Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SophorOx is a proprietary polyphenol-rich antioxidant blend derived from the buds of *Sophora japonica* L (also known as *Styphnolobium japonicum*), standardized to contain at least 90% flavonoids. Its primary active components are quercetin and rutin. Developed as a natural supplement, it is designed to reduce oxidative stress and inflammation in overweight or obese individuals. Mechanistically, it acts by inhibiting pro-inflammatory cytokines such as TNF-α and IL-6 and reducing markers of oxidative stress including malondialdehyde (MDA), 8-isoprostane (8-iso-PGF2α), and 8-hydroxydeoxyguanosine (8-OHdG). Human clinical studies have shown that supplementation with SophorOx leads to significant reductions in oxidative stress biomarkers, improvements in body composition metrics such as weight and waist circumference, and enhanced quality of life measures. Preclinical studies further support its anti-inflammatory effects without notable adverse events[1][2][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SophorOx.